作为EGFR抑制剂的贝蒂基衍生物的设计和合成
Xiaotian Xu1, Huan He1, Qian Guo1
1NMPA Key Laboratory for Research and Evaluation of Drug Metabolism & Guangdong Provincial Key Laboratory of New Drug Screening & Guangdong-Hongkong-Macao Joint Laboratory for New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China.
新的贝蒂基衍生物显示出作为非小细胞肺癌中表皮生长因子受体 (EGFR) 新型全抑制剂的前景. 化合物2b有效地抑制癌细胞的增殖并诱导细胞亡,为抗药性提供了潜在的新策略.
科学领域:
- 在瘤学瘤学.
- 药用化学 医学化学
- 分子生物学分子生物学
背景情况:
- 表皮生长因子受体 (EGFR) 是非小细胞肺癌 (NSCLC) 的关键驱动因素.
- 现有的EGFR氨酸激酶抑制剂 (TKI) 面临着获得药物耐药性的挑战.
- 性EGFR抑制剂通过与ATP竞争性抑制剂相比,与不同的部位结合提供了另一种治疗策略.
研究的目的:
- 设计和合成新的贝蒂基衍生物作为潜在的全性EGFR抑制剂.
- 评估这些衍生物对NSCLC细胞系的抗增殖活性和作用机制.
- 为了研究EGFR全囊中最强效的化合物的结合模式.
主要方法:
- 基于结构的虚拟选,以识别最初的打击化合物ZINC49691377 (1a).
- 通过替代物修饰设计和合成一个通过替代物修饰的贝蒂基衍生物的聚焦库.
- 在实验室中使用NSCLC细胞系 (H1975) 和具有特定EGFR突变的Ba/F3细胞 (L858R/T790M/C797S) 的抗增殖试验.
- 细胞周期分析和细胞亡测定.
- 分子对接和动力学模拟以预测结合相互作用.
主要成果:
- 化合物2b对H1975细胞 (IC50 = 0.40 ± 0.01 μM) 和Ba/F3-EGFR^(L858R/T790M/C797S) 细胞 (IC50 = 2.36 ± 0.33 μM) 表现出强大的抗增殖活性.
- 在H1975细胞中使用2b诱导的G0/G1细胞周期停止治疗.
- 化合物2b在两个测试细胞系中引发了显著的细胞亡.
- 分子建模证实了EGFR的全囊内2b的稳定结合.
结论:
- 贝蒂基衍生物代表了一种用于开发全性EGFR抑制剂的新型化学型.
- 化合物2b显示出作为抗癌剂对EGFR驱动的NSCLC的显著潜力,包括耐药形式.
- 这些贝蒂基衍生物的进一步开发可能会为NSCLC患者带来新的治疗选择.
更多相关视频
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
相关概念视频
Structure-Activity Relationships and Drug Design
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
Mitogens and the Cell Cycle
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
Targeted Cancer Therapies
There are several types of targeted therapies against...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
Adrenergic Agonists: Chemistry and Structure-Activity Relationship
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
